A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/or Breastfeeding.

RecruitingOBSERVATIONAL

Enrollment

279

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

January 31, 2033

Study Completion Date

December 31, 2033

Conditions

Myasthenia GravisCIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

BIOLOGICAL

Efgartigimod

Efgartigimod IV or SC

Trial Locations (1)

RECRUITING

United BioSource LLC, Morgantown